Markets

A troubling link has been found between a cutting-edge gene-editing technology and cancer — and it’s sending biotech stocks tumbling

Two independent studies by Novartis and Karolinska Institute showed that CRISPR-Cas9 may increase the risk for cancer by disrupting function of the essential p53 DNA repair protein. CRISPR Therapeutics‘ stock was down 15.3% Monday morning, while Editas and Intellia, two other companies developing CRISPR-related therapies dropped 7% and 8% respectively. […]
A troubling link has been found between a cutting-edge gene-editing technology and cancer  —  and it’s sending biotech stocks tumbling